Nautilus shares rise 11.72% intraday as Baylor College of Medicine becomes first early access client for Voyager platform in high-resolution cancer heterogeneity analysis.

Nautilus Biotechnology surged 11.72% intraday, announcing that Baylor College of Medicine became its first early access program customer for the Voyager platform on March 18, 2026. The platform focuses on single-molecule proteomics, targeting large pharmaceutical and biotechnology companies. The company develops the Voyager platform to advance high-resolution cancer heterogeneity analysis through computational multi-omics toolkits, aiming to address unmet needs in precision oncology research.